期刊文献+

血清CA199在上皮性卵巢癌中的临床意义 被引量:14

Clinical Significance of Serum CA199 in Patients with Epithelial Ovarian Carcinoma
下载PDF
导出
摘要 目的:探讨上皮性卵巢癌患者血清CA199水平与临床病理学特征的关系及其对预后的影响。方法:用电化学发光免疫分析法测定118例上皮性卵巢癌患者血清CA199、CA125水平,分析其与临床病理特征的关系及其对预后的影响。结果:非浆液性卵巢癌中血清CA199水平及阳性率高于浆液性卵巢癌(P<0.05);非浆液性卵巢癌中术前CA199水平阳性率Ⅲ期患者高于Ⅰ期和Ⅱ期患者(P<0.05),G1、G2级高于G3级(P<0.05),复发组高于未复发组(P<0.05);多因素分析表明临床分期和术前CA199水平对非浆液性卵巢癌预后有影响;用CA199升高预测复发的敏感性和特异性分别为50.00%和93.55%。结论:血清CA199对非浆液性卵巢癌的敏感性高于其对浆液性卵巢癌的敏感性,非浆液性卵巢癌患者术前CA199水平与其临床分期及病理分级密切相关,术后继续监测其水平对预测复发有一定的指导意义。 Objective:To study the effect of the serum level of CA199 on clinical and histological features in patients with epithelial ovarian carcinoma, and prognostic value thereof. Methods: The serum levels of CA199 and CA125 were measured using electrochemiluminescence immunoassay in 118 patients with epithelial ovarian carcinoma. The serum levels of CA199 and CA125, clinical features and prognostic value were carried out retrospectively. Results:The sensibility of CA199 in patients with nonserous epithelial ovarian carcinoma was much higher than that in serous epithelial ovarian carcinoma (P 〈 0.05). In patients with nonserous epithelial ovarian carcinoma, the preoperative serum level of CA199 was more higher in stage Ⅲ patients than that of patients in stage Ⅰ and Ⅱ and much higher in patients of grade 1 and 2 than that in patients of grade 3 (P 〈 0.05). The preoperative serum levels of CA199 were higher in recurrent patients than that in patients of unreeurrent group (P 〈 0.05). The analysis of prognostic multi-factors showed that FIGO stage and the preoperative serum levels of CA199 were prognostic factors. The sensibility and specificity to predict recurrence using the increase level of serum CA199 were 50.00% and 93.55%. Conclusion :The sensibility of serum level CA 199 in patients with non-serous epithelial ovarian carcinoma was much higher than that in patients with serous epithelial ovarian carcinoma. The preoperative serum levels of CA199 were related to the histological type, FIGO stage and differentiation(P 〈 0.05 ),which can help us in the early detection of recurrence.
出处 《天津医药》 CAS 北大核心 2009年第3期186-188,共3页 Tianjin Medical Journal
关键词 CA-19-9抗原 CA-125抗原 卵巢肿瘤 化学发光测定法 预后 CA-19-9 antigen CA-125 antigen ovarian neoplasms chemiluminescent measurements prognosis
  • 相关文献

参考文献9

  • 1Markman M, Markman J, Webster K ,et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer, implications for patient management and clinical trial design[J]. J Clin Oncol, 2004,22(15):3120- 3125.
  • 2Ugorski M ,Laskowska A.Sialyl Lewis (a):A tumor associated carbonydrate antigen involved in adhesion and metastatic potential of caner cells[J].Acta Biochim Pol,2002,49(2) : 303-311.
  • 3Verma S, Li SH, Badiwada MV, et al.Endothelin antagoniam and interleukin-6 inhibition attenuate the proatherogenie effects of C- reactive protein[J]. Circulation ,2002,105(16): 1890-1896.
  • 4Fioretti P, Gaddueei A, Ferdeghini M, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients[J].Gynecol Oncol, 1992,44(2): 155-160.
  • 5余剑英,李菁.血清CA125、CA199在卵巢浆、粘液性囊腺癌术前诊断价值[J].中国医师杂志,2004,6(10):1425-1426. 被引量:13
  • 6Gadducci A, Feroleghihi M ,Prontera C,et al.The Concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses :relevance for differential diagnosis[J].Gynecol Oncol, 1992, 44(1): 147-154.
  • 7刘晓川,孟垂华,刘铁夫,梁桃.胰液K-ras密码子点突变联合血清CA 199水平与胰腺癌复发关系的研究[J].临床消化病杂志,2006,18(2):95-97. 被引量:3
  • 8Rubin SC, Hoskins WJ, Saigo PE, et al.Prognostic factors for recurrence following negative second-look laparoctomy in ovarian cancer patients treated with platinum-based chemotherapy[J].Gynecol Oncol, 1991,42(2) : 137-141.
  • 9杨静华,冯莉,李丽,马志敏.OPN、CA125和CA199检测对卵巢上皮癌诊断和预后的价值[J].中国计划生育学杂志,2007,15(12):740-742. 被引量:5

二级参考文献22

  • 1秦晓光.肿瘤标志物应用中的若干问题[J].中华医学检验杂志,1995,18(4):197-198. 被引量:14
  • 2付建武.妇科肿瘤标记物及其临床应用[J].国外医学(妇产科学分册),1995,22(4):208-211. 被引量:7
  • 3Fioretti P, Gadducci A, Ferdeghini M, et al. The concomitant determination of differeat serum tumor markers in epithelial ovanian carcinoma. Reveleance for monitoring the response to chemocherapy and follow up of patients Gyneclo [J]. One ol, 1992,44:155
  • 4Klapdor R. Tumour markers in clinical oncology an overview[M]. Italy:Sorin Biomedica, 1994,127,140 - 142
  • 5Igor B, Borut G. preoperative value of CA125 as a reflection of tumor grade in epithelial ovarian cancer cancer[J]. Gynecol oncol, 1996,63:166- 168
  • 6LUTTGES J,SCHLEHE B,MENKE MA,et al.The K-ras mutation pattern in pancreatic ductal; adenocarcinom a usually is identical to that in associated normal,hyperplastic,and metaplastic ductal epithelium[J].Cancer,1999,85 (8):1703.
  • 7THEODOR L,MELZER E,SOLOGOY M,et al.Detection of pancreatic carcinoma:diagnostic value of K-ras mutations in circulating DNA from serum[J].Dig Dis Sci,1999,44(10):2014.
  • 8HIGUCHI T,KIKUCHI M,QKAZAKI M.Hepatocellular carcinoma after transantheter hepatic arterial embolication[J].Cancer,1994,73 ;2259.
  • 9AZECHI H,NISHIDA N,FUKUDA Y,et al.Disruption of the p16/cyclin D1/rctinoblastom a protein pathway in the majority of human hepatocellular carcinomas[J].Oncology,2001,60 (4):346.
  • 10TADA M,OMATA M,KAWAI S,et al,Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma[J].Cancer Res,1993,53 (11):2472.

共引文献18

同被引文献135

引证文献14

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部